Study summary · research use only
[Thymogen in the treatment of type-1 diabetes mellitus]
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This study assessed thymogen in patients with type 1 diabetes mellitus who had clinical and laboratory evidence of secondary immunodeficiency. The abstract reports that thymogen removed signs of secondary immunodeficiency, which the authors attribute to activation of T-lymphocyte differentiation. A clinical response was registered in 94.4% and a laboratory response in 83.3% of patients, and a scheme of thymogen administration is suggested.
Abstract
Thymogen effect was assessed in patients with type 1 diabetes mellitus with clinical and laboratory evidence of secondary immunodeficiency. It was found that thymogen removes signs of secondary immunodeficiency due to activation of T-lymphocyte differentiation. Clinical effect of thymogen was registered in 94.4%, laboratory effect in 83.3% of patients. The scheme of thymogen administration is suggested.
pepmg summarizes the peer-reviewed literature and links to every source. It sells nothing and ships nothing. Where an FDA label, a peer-reviewed study or a clinical-trial registry entry (labeled trial registry, not peer-reviewed) has published a dose, pepmg reports it with the source named; it gives no personalized recommendations and no administration technique. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.